You cannot compare Afterpay and BRN.
Afterpay is fintech, 100% information based products with no substantial IP to speak of. I cannot understand the valuation for the takeover - unprofitable business, sure it's growing and it has a massive customer base, but there's nothing really stopping anyone else offering a similar product (cases in point, Zip or even the old institutional banks). Nobody has loyalty to a company like Afterpay - you go with who will give you the credit.
BRN has ownership of a technology with no known comparison - whose use cases are only limited by the ingenuity of its customers.
As to making commercial agreements while the "price and momentum is hot" - if you're a CEO, onto a winner of a company like BRN, running the company with one eye on "what the market is doing" is a sure fire way to ruin the business. Development and deployment plans, product release cycles cannot be changed to suit the whims of the market. It's like trying to drive a race car whilst adjusting your drive style to what the commentators are saying.
- Forums
- ASX - By Stock
- BRN
- 2022 BRN Discussion
2022 BRN Discussion, page-5055
-
- There are more pages in this discussion • 5,868 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BRN (ASX) to my watchlist
|
|||||
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $361.9M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 49672 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.0¢ | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 49672 | 0.210 |
1 | 1000 | 0.205 |
16 | 320678 | 0.200 |
63 | 1475597 | 0.195 |
60 | 1662070 | 0.190 |
Price($) | Vol. | No. |
---|---|---|
0.170 | 2000 | 1 |
0.175 | 43000 | 1 |
0.185 | 32000 | 1 |
0.190 | 10000 | 1 |
0.195 | 211042 | 13 |
Last trade - 09.52am 16/07/2024 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online